ETHICAL CONCERNS REGARDING COMMERCIALIZATION OF DEEP BRAIN STIMULATION FOR OBSESSIVE COMPULSIVE DISORDER
The United States Food and Drug Administration's recent approval of the commercial use of Deep Brain Stimulation (DBS) as a treatment for Obsessive Compulsive Disorder (OCD) will be discussed within the context of the existing USA regulatory framework. The purpose will be to illustrate the curr...
| Main Author: | |
|---|---|
| Format: | Electronic Article |
| Language: | English |
| Check availability: | HBZ Gateway |
| Interlibrary Loan: | Interlibrary Loan for the Fachinformationsdienste (Specialized Information Services in Germany) |
| Published: |
2012
|
| In: |
Bioethics
Year: 2012, Volume: 26, Issue: 8, Pages: 440-446 |
| Further subjects: | B
innovative surgery
B neurotechnology B Oversight B Bioethics B Regulation B deep brain stimulation B industry-driven approach B Obsessive Compulsive Disorder |
| Online Access: |
Presumably Free Access Volltext (lizenzpflichtig) Volltext (lizenzpflichtig) |
